The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform
M. Ninomiya - One of the best experts on this subject based on the ideXlab platform.
-
clinical trial extended treatment duration of Peginterferon Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis c genotype 1 infected late responders
Alimentary Pharmacology & Therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, J Sugihara, E Tomita, M. NinomiyaAbstract:Summary Background The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. Aim To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. Methods A total of 120 treatment-naive or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 μg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12–48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 μg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Results Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Conclusion Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
-
Clinical trial: extended treatment duration of Peginterferon-Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Alimentary pharmacology & therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, Sugihara J, Tomita E, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, M. NinomiyaAbstract:The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. A total of 120 treatment-naïve or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 microg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12-48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
Masahito Nagaki - One of the best experts on this subject based on the ideXlab platform.
-
clinical trial extended treatment duration of Peginterferon Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis c genotype 1 infected late responders
Alimentary Pharmacology & Therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, J Sugihara, E Tomita, M. NinomiyaAbstract:Summary Background The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. Aim To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. Methods A total of 120 treatment-naive or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 μg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12–48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 μg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Results Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Conclusion Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
-
Clinical trial: extended treatment duration of Peginterferon-Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Alimentary pharmacology & therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, Sugihara J, Tomita E, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, M. NinomiyaAbstract:The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. A total of 120 treatment-naïve or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 microg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12-48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
Hironori Mitsuyoshi - One of the best experts on this subject based on the ideXlab platform.
-
simple formula to predict response to Peginterferon Alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis c patients with high viral loads
Hepatology Research, 2011Co-Authors: Yoshito Itoh, Takeshi Nishimura, Hiroaki Hashimoto, Kanji Yamaguchi, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Kohichiroh Yasui, Hironori MitsuyoshiAbstract:Aim: We advocate a simple formula which can conveniently predict the outcome of Peg-interferon (IFN) Alpha2b and ribavirin (RBV) combination therapy for genotype 1 chronic hepatitis C (CH-C) with high viral load. Methods: A total of 338 (group A: 230, Group B: 108) genotype 1 CH-C patients treated with Peg-IFN alfa-2b and RBV were enrolled. Clinical parameters differing significantly between sustained virological responders (SVRs) and non-SVRs in group A were categorized, then a simple formula to predict SVR was constructed and re-evaluated in group B. Another formula containing hepatitis C virus amino acid mutations/substitutions also was constructed. Results: In group A, gender and HCV RNA load <1000 KIU were significant predictors of SVR by multivariate logistic regression analysis. A simple formula was constructed (formula A): male gender (point 2) + HCV RNA load <1000 KIU (3) + platelet counts ≥15 × 104 /mm3 (1) + age <60 (1). In group A, score (0–1) predicted SVR rate 23.8% (2–4): 48.1% and (5–7): 70.2%. According to this formula, score (0–1) predicted SVR rate 7.1% (2–4): 38.6%, and (5–7): 70.3% in group B. Information on HCV amino acid mutations/substitutions seemed to add some accuracy. Conclusions: This simple formula can be used to roughly determine, at the patients' first/second visit, the probability of response to Peg-IFN Alpha2b and RBV combination therapy for genotype 1 CH-C with high viral load.
-
Simple formula to predict response to Peginterferon Alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
Hepatology research : the official journal of the Japan Society of Hepatology, 2011Co-Authors: Yoshito Itoh, Takeshi Nishimura, Hiroaki Hashimoto, Kanji Yamaguchi, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Kohichiroh Yasui, Hironori MitsuyoshiAbstract:Aim: We advocate a simple formula which can conveniently predict the outcome of Peg-interferon (IFN) Alpha2b and ribavirin (RBV) combination therapy for genotype 1 chronic hepatitis C (CH-C) with high viral load. Methods: A total of 338 (group A: 230, Group B: 108) genotype 1 CH-C patients treated with Peg-IFN alfa-2b and RBV were enrolled. Clinical parameters differing significantly between sustained virological responders (SVRs) and non-SVRs in group A were categorized, then a simple formula to predict SVR was constructed and re-evaluated in group B. Another formula containing hepatitis C virus amino acid mutations/substitutions also was constructed. Results: In group A, gender and HCV RNA load
C. Sano - One of the best experts on this subject based on the ideXlab platform.
-
clinical trial extended treatment duration of Peginterferon Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis c genotype 1 infected late responders
Alimentary Pharmacology & Therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, J Sugihara, E Tomita, M. NinomiyaAbstract:Summary Background The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. Aim To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. Methods A total of 120 treatment-naive or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 μg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12–48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 μg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Results Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Conclusion Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
-
Clinical trial: extended treatment duration of Peginterferon-Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Alimentary pharmacology & therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, Sugihara J, Tomita E, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, M. NinomiyaAbstract:The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. A total of 120 treatment-naïve or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 microg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12-48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
Masahito Shimizu - One of the best experts on this subject based on the ideXlab platform.
-
clinical trial extended treatment duration of Peginterferon Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis c genotype 1 infected late responders
Alimentary Pharmacology & Therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, J Sugihara, E Tomita, M. NinomiyaAbstract:Summary Background The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. Aim To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. Methods A total of 120 treatment-naive or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 μg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12–48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 μg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Results Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Conclusion Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.
-
Clinical trial: extended treatment duration of Peginterferon-Alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Alimentary pharmacology & therapeutics, 2009Co-Authors: Masahito Nagaki, Masahito Shimizu, Sugihara J, Tomita E, C. Sano, Takafumi Naiki, Kiminori Kimura, K. Amano, T. Sakai, M. NinomiyaAbstract:The benefits of prolonging Peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. A total of 120 treatment-naïve or retreated patients with HCV genotype 1 were treated with Peginterferon-alpha-2b (1.5 microg/kg/week) plus weight-based ribavirin. We had 34 late responders, in whom HCV RNA first became undetectable at week 12-48, and randomized them into three groups receiving standard-dose Peginterferon-alpha-2b plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A), receiving low-dose Peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B) or no extended treatment (group C), and evaluated the outcome according to their virological response. Multivariate analysis showed that the treatment for 96 weeks was identified as a significant, independent factor associated with SVR in HCV genotype 1-infected late responders in comparison with group A [odds ratio (OR), 10.002; P = 0.080] and group C (OR, 17.748; P = 0.025). Extending the treatment duration from 48 weeks to 96 weeks improves SVR rates in genotype 1-infected patients with late virological response to Peginterferon-alpha-2b and ribavirin.